Do analysts rate ALVR or SERA?

Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 180.61%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is ALVR or SERA more profitable?

AlloVir has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Sera Prognostics -47,475.72% -46.71% -34.06%

Do analysts prefer ALVR or ACET?

Adicet Bio has a consensus target price of $46.80, indicating a potential upside of 458.47%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts clearly believe Adicet Bio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Adicet Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has higher earnings and valuation, ALVR or ACET?

Adicet Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is ALVR or ACET more profitable?

AlloVir's return on equity of -71.03% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Adicet Bio N/A -74.90% -60.87%

Do analysts recommend ALVR or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, ALVR or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is ALVR or TELO more profitable?

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Telomir Pharmaceuticals N/A -98.73% -85.85%

Do analysts rate IBIO or ALVR?

iBio currently has a consensus target price of $5.00, suggesting a potential upside of 249.65%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, IBIO or ALVR?

iBio has higher revenue and earnings than AlloVir. iBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 177.61 -$18.38M -$0.58 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is IBIO or ALVR more profitable?

iBio's return on equity of -53.86% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% AlloVir N/A -71.03% -61.27%

Do analysts rate ALVR or ACRV?

Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 592.31%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings and valuation, ALVR or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A

Is ALVR or ACRV more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Acrivon Therapeutics N/A -70.14% -61.60%

AlloVir (ALVR) Competitors

$3.88 -0.06 (-1.52%)

As of 08/13/2026

Compare

ALVR vs. SERA, ACET, TELO, IBIO, and ACRV

Should you buy AlloVir stock or one of its competitors? AlloVir's main competitors and comparable companies include Sera Prognostics (SERA), Adicet Bio (ACET), Telomir Pharmaceuticals (TELO), iBio (IBIO), and Acrivon Therapeutics (ACRV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AlloVir compare to Sera Prognostics?

AlloVir (NASDAQ:ALVR) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Sera Prognostics had 8 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for Sera Prognostics and 0 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 beat Sera Prognostics' score of -0.16 indicating that AlloVir is being referred to more favorably in the media.

Company	Overall Sentiment
AlloVir	Neutral
Sera Prognostics	Neutral

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AlloVir has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Sera Prognostics has higher revenue and earnings than AlloVir. Sera Prognostics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A

Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 180.61%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Summary

Sera Prognostics beats AlloVir on 11 of the 15 factors compared between the two stocks.

How does AlloVir compare to Adicet Bio?

AlloVir (NASDAQ:ALVR) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Adicet Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

In the previous week, Adicet Bio had 12 more articles in the media than AlloVir. MarketBeat recorded 12 mentions for Adicet Bio and 0 mentions for AlloVir. Adicet Bio's average media sentiment score of 1.12 beat AlloVir's score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Adicet Bio	Positive

Adicet Bio has a consensus target price of $46.80, indicating a potential upside of 458.47%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts clearly believe Adicet Bio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

AlloVir's return on equity of -71.03% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Adicet Bio	N/A	-74.90%	-60.87%

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 3.4% of Adicet Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Adicet Bio beats AlloVir on 11 of the 14 factors compared between the two stocks.

How does AlloVir compare to Telomir Pharmaceuticals?

AlloVir (NASDAQ:ALVR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Telomir Pharmaceuticals	N/A	-98.73%	-85.85%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

In the previous week, Telomir Pharmaceuticals had 7 more articles in the media than AlloVir. MarketBeat recorded 7 mentions for Telomir Pharmaceuticals and 0 mentions for AlloVir. Telomir Pharmaceuticals' average media sentiment score of 0.01 beat AlloVir's score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Telomir Pharmaceuticals	Neutral

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

66.1% of AlloVir shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Telomir Pharmaceuticals beats AlloVir on 6 of the 11 factors compared between the two stocks.

How does AlloVir compare to iBio?

iBio (NASDAQ:IBIO) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

iBio's return on equity of -53.86% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
AlloVir	N/A	-71.03%	-61.27%

iBio currently has a consensus target price of $5.00, suggesting a potential upside of 249.65%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.9% of iBio shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

iBio has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

iBio has higher revenue and earnings than AlloVir. iBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	177.61	-$18.38M	-$0.58	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, iBio had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for iBio and 0 mentions for AlloVir. iBio's average media sentiment score of 1.45 beat AlloVir's score of 0.00 indicating that iBio is being referred to more favorably in the media.

Company	Overall Sentiment
iBio	Positive
AlloVir	Neutral

Summary

iBio beats AlloVir on 12 of the 14 factors compared between the two stocks.

How does AlloVir compare to Acrivon Therapeutics?

AlloVir (NASDAQ:ALVR) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market.

In the previous week, Acrivon Therapeutics had 7 more articles in the media than AlloVir. MarketBeat recorded 7 mentions for Acrivon Therapeutics and 0 mentions for AlloVir. Acrivon Therapeutics' average media sentiment score of 1.01 beat AlloVir's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Acrivon Therapeutics	Positive

Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 592.31%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

66.1% of AlloVir shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Acrivon Therapeutics' return on equity of -70.14% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Summary

Acrivon Therapeutics beats AlloVir on 10 of the 12 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.57M	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-0.19	10.68	269.86	25.30
Price / Sales	N/A	1,308.25	601.81	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.13	17.49	13.08	6.33
Net Income	-$190.42M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-7.40%	1.74%	1.12%	1.07%
1 Month Performance	-12.22%	1.60%	1.79%	1.03%
1 Year Performance	70.18%	56.43%	67.69%	20.77%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$3.88 -1.5%	N/A	+58.2%	$19.57M	N/A	N/A	110	High Trading Volume
SERA Sera Prognostics	2.6754 of 5 stars	$1.99 flat	$5.50 +176.4%	-12.6%	$77.93M	$80K	N/A	120	News Coverage Earnings Report
ACET Adicet Bio	3.5016 of 5 stars	$8.31 +1.0%	$46.80 +463.2%	-24.7%	$77.78M	N/A	N/A	90	News Coverage Positive News Analyst Revision
TELO Telomir Pharmaceuticals	0.5321 of 5 stars	$1.10 -2.7%	N/A	-34.4%	$75.65M	N/A	N/A	1	News Coverage Earnings Report
IBIO iBio	3.4597 of 5 stars	$1.50 +2.0%	$5.00 +233.3%	N/A	$74.52M	$400K	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. SERA, ACET, TELO, IBIO, and ACRV

How does AlloVir compare to Sera Prognostics?

Summary

How does AlloVir compare to Adicet Bio?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Summary

How does AlloVir compare to iBio?

Summary

How does AlloVir compare to Acrivon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. SERA, ACET, TELO, IBIO, and ACRV

How does AlloVir compare to Sera Prognostics?

Does the media refer more to ALVR or SERA?

Do institutionals and insiders have more ownership in ALVR or SERA?

Is ALVR or SERA more profitable?

Which has better valuation and earnings, ALVR or SERA?

Do analysts rate ALVR or SERA?

Which has more risk & volatility, ALVR or SERA?

Summary

How does AlloVir compare to Adicet Bio?

Which has higher earnings and valuation, ALVR or ACET?

Which has more volatility and risk, ALVR or ACET?

Does the media favor ALVR or ACET?

Do analysts prefer ALVR or ACET?

Is ALVR or ACET more profitable?

Do institutionals & insiders have more ownership in ALVR or ACET?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Is ALVR or TELO more profitable?

Do analysts recommend ALVR or TELO?

Which has more risk and volatility, ALVR or TELO?

Does the media refer more to ALVR or TELO?

Which has preferable valuation & earnings, ALVR or TELO?

Do insiders & institutionals have more ownership in ALVR or TELO?

Summary

How does AlloVir compare to iBio?

Is IBIO or ALVR more profitable?

Do analysts rate IBIO or ALVR?

Do institutionals and insiders have more ownership in IBIO or ALVR?

Which has more volatility & risk, IBIO or ALVR?

Which has better earnings and valuation, IBIO or ALVR?

Does the media prefer IBIO or ALVR?

Summary

How does AlloVir compare to Acrivon Therapeutics?

Which has more volatility and risk, ALVR or ACRV?

Does the media refer more to ALVR or ACRV?

Do analysts rate ALVR or ACRV?

Do institutionals & insiders have more ownership in ALVR or ACRV?

Is ALVR or ACRV more profitable?

Which has better earnings and valuation, ALVR or ACRV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools